Benefits of Ferric Carboxymaltose Administration for Enhanced Hemoglobin Levels in Urban Population of Sindh: BOFERIN® Observational Study

Authors

  • Jahanara Ainuddin Department of Obstetrics & Gynecology, Dow University of Health Sciences, Karachi, Pakistan.
  • Nasreen Majid Department of Obstetrics & Gynecology, Memon Medical Institute, Karachi, Pakistan
  • Azra Aslam Department of Obstetrics & Gynecology, Shah Bhitai Government Hospital, Hyderabad, Pakistan.
  • Raheel Sikander Department of Obstetrics & Gynecology, Liaquat University of Health Sciences, Hyderabad, Pakistan.
  • Sarmad Iqbal Department of Pharmacy Practice, University of Karachi, Sindh, Pakistan.
  • Syed Saad Hussain Department of Pharmacy, Iqra University, Karachi, Pakistan.

Keywords:

Anemia, Iron-Deficiency, Iron carboxymaltose, Generic drugs, Hemoglobin, Ferric carboxymaltose

Abstract

Background: Iron deficiency anemia is a major public health issue in developing countries, especially among women of reproductive age. Anemia is a major public health problem in women of reproductive age in rural Pakistan and a large proportion of women were found to have low levels of serum iron.
Materials and Methods: A multicenter observational cohort study was conducted at Karachi & Hyderabad from 8th February 2022 to 30th April 2022. Women with low hemoglobin level and age 18-45 years were included in this study. Patients were grouped according to 1-week assessment and 3-week assessment of hemoglobin concentration. A single dose of a generic substituent ferric carboxymaltose (Boferin®) was administered to the patients over 15 minutes infusion. Baseline hemoglobin levels were compared at 1 week and 3 weeks after administration of Ferric Carboxymaltose.
Results: A total of 104 patients were enrolled in this study. The mean hemoglobin levels at baseline were 9.22 ± 0.175 g/dl and 7.55 ± 0.329 g/ dl for 1-week and 3-week, respectively. The mean hemoglobin increases after 1 week and 3 week was reported as 1.4211± 0.169 g/dl (p< 0.001) and 2.321± 0.335 g/dl (p< 0.001) respectively. Only three patients presented with mild to moderate adverse effect which included abdominal discomfort and nausea.
Conclusion: This is a first in class study has shown statistically significant increase in hemoglobin at 1-week and 3-week interval with minimal side effects. It is concluded that Boferin® is efficacious in increasing hemoglobin levels in patients with iron deficiency anemia with its safety being documented in pregnant Pakistani population as well.

Downloads

Published

2023-06-23

How to Cite

1.
Ainuddin J, Majid N, Aslam A, Sikander R, Iqbal S, Hussain SS. Benefits of Ferric Carboxymaltose Administration for Enhanced Hemoglobin Levels in Urban Population of Sindh: BOFERIN® Observational Study. Nat J Health Sci [Internet]. 2023Jun.23 [cited 2024May29];8(2):62-6. Available from: https://ojs.njhsciences.com/index.php/njhs/article/view/398

Issue

Section

Research Article